218 related articles for article (PubMed ID: 37031342)
1. Origin and Evolution of RAS Membrane Targeting.
García-España A; Philips MR
Oncogene; 2023 May; 42(21):1741-1750. PubMed ID: 37031342
[TBL] [Abstract][Full Text] [Related]
2. Origin and evolution of RAS oncoprotein membrane targeting.
García-España A; Philips MR
Res Sq; 2023 Jan; ():. PubMed ID: 36711820
[TBL] [Abstract][Full Text] [Related]
3. Differential functions of the KRAS splice variants.
Kochen Rossi J; Nuevo-Tapioles C; Philips MR
Biochem Soc Trans; 2023 Jun; 51(3):1191-1199. PubMed ID: 37222266
[TBL] [Abstract][Full Text] [Related]
4. Ras protein abundance correlates with Ras isoform mutation patterns in cancer.
Hood FE; Sahraoui YM; Jenkins RE; Prior IA
Oncogene; 2023 Apr; 42(15):1224-1232. PubMed ID: 36864243
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of KRAS4a and KRAS4b splice variants reveals distinctive structural and functional properties.
Whitley MJ; Tran TH; Rigby M; Yi M; Dharmaiah S; Waybright TJ; Ramakrishnan N; Perkins S; Taylor T; Messing S; Esposito D; Nissley DV; McCormick F; Stephen AG; Turbyville T; Cornilescu G; Simanshu DK
Sci Adv; 2024 Feb; 10(7):eadj4137. PubMed ID: 38354232
[No Abstract] [Full Text] [Related]
6. Organization of Farnesylated, Carboxymethylated KRAS4B on Membranes.
Barklis E; Stephen AG; Staubus AO; Barklis RL; Alfadhli A
J Mol Biol; 2019 Sep; 431(19):3706-3717. PubMed ID: 31330153
[TBL] [Abstract][Full Text] [Related]
7. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
8. Membrane interactions of the globular domain and the hypervariable region of KRAS4b define its unique diffusion behavior.
Goswami D; Chen D; Yang Y; Gudla PR; Columbus J; Worthy K; Rigby M; Wheeler M; Mukhopadhyay S; Powell K; Burgan W; Wall V; Esposito D; Simanshu DK; Lightstone FC; Nissley DV; McCormick F; Turbyville T
Elife; 2020 Jan; 9():. PubMed ID: 31958057
[TBL] [Abstract][Full Text] [Related]
9. Conserved allosteric perturbation of the GTPase domains by region 1 of Ras hypervariable regions.
Gu X; Zhang Y; Long D
Biophys J; 2024 Apr; 123(7):839-846. PubMed ID: 38419331
[TBL] [Abstract][Full Text] [Related]
10. KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform.
Salmón M; Paniagua G; Lechuga CG; Fernández-García F; Zarzuela E; Álvarez-Díaz R; Musteanu M; Guerra C; Caleiras E; Muñoz J; Ortega S; Drosten M; Barbacid M
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301865
[TBL] [Abstract][Full Text] [Related]
11. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of isoform-specific residue influence on GTP-bound HRas, KRas, and NRas.
Volmar AY; Guterres H; Zhou H; Reid D; Pavlopoulos S; Makowski L; Mattos C
Biophys J; 2022 Oct; 121(19):3616-3629. PubMed ID: 35794829
[TBL] [Abstract][Full Text] [Related]
13. Validation of Isoform- and Mutation-Specific RAS Antibodies.
Waters AM; Der CJ
Methods Mol Biol; 2021; 2262():91-103. PubMed ID: 33977472
[TBL] [Abstract][Full Text] [Related]
14. The Abundance of KRAS and RAS Gene Mutations in Cancer.
Stites EC
Methods Mol Biol; 2024; 2797():13-22. PubMed ID: 38570449
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
16. Flexible-body motions of calmodulin and the farnesylated hypervariable region yield a high-affinity interaction enabling K-Ras4B membrane extraction.
Jang H; Banerjee A; Chavan T; Gaponenko V; Nussinov R
J Biol Chem; 2017 Jul; 292(30):12544-12559. PubMed ID: 28623230
[TBL] [Abstract][Full Text] [Related]
17. The role of KRAS splice variants in cancer biology.
Nuevo-Tapioles C; Philips MR
Front Cell Dev Biol; 2022; 10():1033348. PubMed ID: 36393833
[TBL] [Abstract][Full Text] [Related]
18. Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A.
Zhao H; Liu P; Zhang R; Wu M; Li D; Zhao X; Zhang C; Jiao B; Chen B; Chen Z; Ren R
J Hematol Oncol; 2015 Dec; 8():132. PubMed ID: 26715448
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic KRas mobility in the membrane and signaling response.
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():109-113. PubMed ID: 29499269
[TBL] [Abstract][Full Text] [Related]
20. Quantification of spatiotemporal patterns of Ras isoform expression during development.
Newlaczyl AU; Coulson JM; Prior IA
Sci Rep; 2017 Jan; 7():41297. PubMed ID: 28117393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
